Viral Vector Plasmid DNA Manufacturing Market Size, Share & Trends

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Viral Vector Plasmid DNA Manufacturing Market Size Analysis

Global Viral Vector Plasmid DNA Manufacturing Market Introduction
By Vector-Type
1. Introduction
  1. Vector-Type By Value
2. AAV
  1. By Value
3. Retrovirus
  1. By Value
4. Adenovirus
  1. By Value
5. Plasmids
  1. By Value
6. Lentivirus
  1. By Value
7. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
  1. By Value
3. Downstream {Purification, Fill-Finish}
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Antisense and RNAi
  1. By Value
3. Gene Therapy
  1. By Value
4. Cell Therapy
  1. By Value
5. Vaccinology
  1. By Value
6. Research Applications
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Research Institutes
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
5. Others
  1. By Value

North America Market Analysis

Introduction
By Vector-Type
1. Introduction
  1. Vector-Type By Value
2. AAV
  1. By Value
3. Retrovirus
  1. By Value
4. Adenovirus
  1. By Value
5. Plasmids
  1. By Value
6. Lentivirus
  1. By Value
7. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
  1. By Value
3. Downstream {Purification, Fill-Finish}
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Antisense and RNAi
  1. By Value
3. Gene Therapy
  1. By Value
4. Cell Therapy
  1. By Value
5. Vaccinology
  1. By Value
6. Research Applications
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Research Institutes
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
5. Others
  1. By Value
U.S.
1. By Vector-Type
  1. Introduction
    1. Vector-Type By Value
  2. AAV
    1. By Value
  3. Retrovirus
    1. By Value
  4. Adenovirus
    1. By Value
  5. Plasmids
    1. By Value
  6. Lentivirus
    1. By Value
  7. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
    1. By Value
  3. Downstream {Purification, Fill-Finish}
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Antisense and RNAi
    1. By Value
  3. Gene Therapy
    1. By Value
  4. Cell Therapy
    1. By Value
  5. Vaccinology
    1. By Value
  6. Research Applications
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Research Institutes
    1. By Value
5. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Others
    1. By Value
Canada

Europe Market Analysis

Introduction
By Vector-Type
1. Introduction
  1. Vector-Type By Value
2. AAV
  1. By Value
3. Retrovirus
  1. By Value
4. Adenovirus
  1. By Value
5. Plasmids
  1. By Value
6. Lentivirus
  1. By Value
7. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
  1. By Value
3. Downstream {Purification, Fill-Finish}
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Antisense and RNAi
  1. By Value
3. Gene Therapy
  1. By Value
4. Cell Therapy
  1. By Value
5. Vaccinology
  1. By Value
6. Research Applications
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Research Institutes
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
5. Others
  1. By Value
U.K.
1. By Vector-Type
  1. Introduction
    1. Vector-Type By Value
  2. AAV
    1. By Value
  3. Retrovirus
    1. By Value
  4. Adenovirus
    1. By Value
  5. Plasmids
    1. By Value
  6. Lentivirus
    1. By Value
  7. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
    1. By Value
  3. Downstream {Purification, Fill-Finish}
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Antisense and RNAi
    1. By Value
  3. Gene Therapy
    1. By Value
  4. Cell Therapy
    1. By Value
  5. Vaccinology
    1. By Value
  6. Research Applications
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Research Institutes
    1. By Value
5. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Others
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Vector-Type
1. Introduction
  1. Vector-Type By Value
2. AAV
  1. By Value
3. Retrovirus
  1. By Value
4. Adenovirus
  1. By Value
5. Plasmids
  1. By Value
6. Lentivirus
  1. By Value
7. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
  1. By Value
3. Downstream {Purification, Fill-Finish}
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Antisense and RNAi
  1. By Value
3. Gene Therapy
  1. By Value
4. Cell Therapy
  1. By Value
5. Vaccinology
  1. By Value
6. Research Applications
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Research Institutes
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
5. Others
  1. By Value
China
1. By Vector-Type
  1. Introduction
    1. Vector-Type By Value
  2. AAV
    1. By Value
  3. Retrovirus
    1. By Value
  4. Adenovirus
    1. By Value
  5. Plasmids
    1. By Value
  6. Lentivirus
    1. By Value
  7. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
    1. By Value
  3. Downstream {Purification, Fill-Finish}
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Antisense and RNAi
    1. By Value
  3. Gene Therapy
    1. By Value
  4. Cell Therapy
    1. By Value
  5. Vaccinology
    1. By Value
  6. Research Applications
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Research Institutes
    1. By Value
5. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Others
    1. By Value
Korea
Japan
India
Australia
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Vector-Type
1. Introduction
  1. Vector-Type By Value
2. AAV
  1. By Value
3. Retrovirus
  1. By Value
4. Adenovirus
  1. By Value
5. Plasmids
  1. By Value
6. Lentivirus
  1. By Value
7. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
  1. By Value
3. Downstream {Purification, Fill-Finish}
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Antisense and RNAi
  1. By Value
3. Gene Therapy
  1. By Value
4. Cell Therapy
  1. By Value
5. Vaccinology
  1. By Value
6. Research Applications
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Research Institutes
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
5. Others
  1. By Value
UAE
1. By Vector-Type
  1. Introduction
    1. Vector-Type By Value
  2. AAV
    1. By Value
  3. Retrovirus
    1. By Value
  4. Adenovirus
    1. By Value
  5. Plasmids
    1. By Value
  6. Lentivirus
    1. By Value
  7. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
    1. By Value
  3. Downstream {Purification, Fill-Finish}
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Antisense and RNAi
    1. By Value
  3. Gene Therapy
    1. By Value
  4. Cell Therapy
    1. By Value
  5. Vaccinology
    1. By Value
  6. Research Applications
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Research Institutes
    1. By Value
5. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Others
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Vector-Type
1. Introduction
  1. Vector-Type By Value
2. AAV
  1. By Value
3. Retrovirus
  1. By Value
4. Adenovirus
  1. By Value
5. Plasmids
  1. By Value
6. Lentivirus
  1. By Value
7. Others
  1. By Value
By Workflow
1. Introduction
  1. Workflow By Value
2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
  1. By Value
3. Downstream {Purification, Fill-Finish}
  1. By Value
By Application
1. Introduction
  1. Application By Value
2. Antisense and RNAi
  1. By Value
3. Gene Therapy
  1. By Value
4. Cell Therapy
  1. By Value
5. Vaccinology
  1. By Value
6. Research Applications
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Pharmaceutical and Biopharmaceutical Companies
  1. By Value
3. Research Institutes
  1. By Value
By Disease
1. Introduction
  1. Disease By Value
2. Cancer
  1. By Value
3. Genetic Disorders
  1. By Value
4. Infectious Diseases
  1. By Value
5. Others
  1. By Value
Brazil
1. By Vector-Type
  1. Introduction
    1. Vector-Type By Value
  2. AAV
    1. By Value
  3. Retrovirus
    1. By Value
  4. Adenovirus
    1. By Value
  5. Plasmids
    1. By Value
  6. Lentivirus
    1. By Value
  7. Others
    1. By Value
2. By Workflow
  1. Introduction
    1. Workflow By Value
  2. Upstream {Vector Amplification and Expansion, Vector Recovery/Harvesting}
    1. By Value
  3. Downstream {Purification, Fill-Finish}
    1. By Value
3. By Application
  1. Introduction
    1. Application By Value
  2. Antisense and RNAi
    1. By Value
  3. Gene Therapy
    1. By Value
  4. Cell Therapy
    1. By Value
  5. Vaccinology
    1. By Value
  6. Research Applications
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Pharmaceutical and Biopharmaceutical Companies
    1. By Value
  3. Research Institutes
    1. By Value
5. By Disease
  1. Introduction
    1. Disease By Value
  2. Cancer
    1. By Value
  3. Genetic Disorders
    1. By Value
  4. Infectious Diseases
    1. By Value
  5. Others
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Viral Vector Plasmid DNA Manufacturing Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Wuxi Bio
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Shanghai Chem Partner Co. Ltd.
GenScript
MabPlex
Wuxi AppTech
JHL Biotech
Boehringer Ingelheim
ThousandOAKS Biopharmaceuticals
Autek Bio
Seneca Biopharma
JW Therapeutics (Shanghai) Co Ltd.
Shanghai Cell Therapeutics Group Co. Ltd
APTBIO
Shanghai ZhenGe Biotech
Shanghai OPM Biosciences
Shenzhen SiBiono Gene Tech Co. Ltd.

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment